Phase 1 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 65 who have been newly diagnosed with a specific type of throat cancer (oropharyngeal squamous cell carcinoma) that has tested positive for both p16 and HPV16, and has reached an advanced but locally contained stage (confirm specific staging details with trial site)
• People whose cancer has not spread to distant parts of the body (secondary HPV16-positive tumours are allowed)
• People whose main tumour can be reached for a tissue sample and for direct injection as part of the treatment
• People who are in reasonably good general health, able to carry out normal activity with only minor limitations (confirm with trial site)
• People with a life expectancy of at least 6 months
• People with a normal or near-normal heart tracing (ECG) at the screening stage
• Women who could potentially become pregnant must have a negative blood pregnancy test at the start of the study
• People who agree to use reliable contraception for the full duration of the study treatment
• People who are willing and able to provide written consent to participate

Who may not be able to join:

• People whose cancer has already spread to distant parts of the body
• People who have another active cancer that is not related to HPV16
• People with a history of any other cancer, unless it was fully cleared at least 2 years before joining and no further treatment for it is needed during the study
• People with significantly abnormal blood, kidney, or liver test results that cannot be explained by their current illness
• People who have had any vaccine within 1 week before the study start date
• People who have had an active significant viral infection (such as flu, CMV, or EBV) within 4 weeks before starting the study treatment
• People who have hepatitis B, hepatitis C, HIV, or any other condition that weakens the immune system
• People who have had a flu-like illness within 4 weeks before the study start date
• People with a known allergy or sensitivity to Tamiflu or any of its ingredients
• People who are pregnant or breastfeeding
• People with a serious ongoing illness, including an active infection requiring treatment
• People with confirmed or suspected lupus, thyroid inflammation, inflammatory bowel disease (including Crohn's disease), or multiple sclerosis
• People who are taking medications that suppress the immune system, including ongoing steroid tablets, certain anti-rheumatic drugs (such as azathioprine, methotrexate, or cyclosporine), or biological therapies (such as infliximab or adalimumab) — steroid eye drops or ear drops are allowed
• People who have had major surgery within 4 weeks before the study start date
• People with significant ongoing heart, liver, or kidney disease, or a history of serious unstable conditions such as heart failure, heart attack, or severe irregular heartbeat
• People who have taken part in another clinical trial or used an experimental drug within 2 months before the study start date
• People who, in the treating doctor's judgement, may not be able to participate safely or may affect the study results
• People who are unable to follow the study's requirements

Important: Always verify eligibility with the trial site directly before applying.